-
公开(公告)号:US11608491B2
公开(公告)日:2023-03-21
申请号:US16798193
申请日:2020-02-21
Applicant: LIFE TECHNOLOGIES CORPORATION
Inventor: Xin Yu , Xavier de Mollerat du Jeu , Chao Yan Liu , Jian Liu , Jonathan Zmuda
Abstract: The instant technology relates to a production system to produce AAV vectors in a serum free suspension platform and at high titers. This technology uses reagents comprising media, cells, transfection reagent, AAV enhancer, and a lysis buffer, each of which is designed to provide maximal AAV production from suspension culture of mammalian cells, e.g. HEK293 cells. With this new system we are able to deliver up to about 2×1011 viral genomes per milliliter (vg/mL) of unconcentrated AAV vectors.
-
公开(公告)号:US10066000B2
公开(公告)日:2018-09-04
申请号:US13886226
申请日:2013-05-02
Applicant: LIFE TECHNOLOGIES CORPORATION
Inventor: Sanjay Vasu , Henry Chiou , Jeffrey Rogers , Maria Isabel Cisneros , Jingqiu Li , Chao Yan Liu , Meredith Jones
IPC: C12P21/02 , C12N5/02 , C07K14/505 , C12N5/00 , C12N5/07 , C12N5/073 , C12N5/10 , C12N5/16 , C12N5/22
Abstract: High-Yield mammalian transient expression systems can include a cell culture media (particularly serum free, non animal derived, and/or chemically defined media) for introducing macromolecules and compounds (e.g., nucleic acid molecules) into cells (e.g., eukaryotic cells). Cells containing such introduced materials can then be cultured in the cell culture media. In particular, the invention allows introduction of nucleic acid molecules (e.g., vectors) into cells (particularly mammalian cells) and expression of proteins encoded by the nucleic acid molecules in the cells. The invention obviates the need to change the cell culture medium each time a different procedure is performed with the cells (e.g., culturing cells vs. transfecting cells). The invention also relates to compositions and kits useful for culturing and transforming/transfecting cells.
-
公开(公告)号:US20200270583A1
公开(公告)日:2020-08-27
申请号:US16798193
申请日:2020-02-21
Applicant: LIFE TECHNOLOGIES CORPORATION
Inventor: Xin YU , Xavier de MOLLERAT du JEU , Chao Yan Liu , jJian Liu , Jonathan Zmuda
Abstract: The instant technology relates to a production system to produce AAV vectors in a serum free suspension platform and at high titers. This technology uses reagents comprising media, cells, transfection reagent, AAV enhancer, and a lysis buffer, each of which is designed to provide maximal AAV production from suspension culture of mammalian cells, e.g. HEK293 cells. With this new system we are able to deliver up to about 2×1011 viral genomes per milliliter (vg/mL) of unconcentrated AAV vectors.
-
-